$ALNY
ALNYLAM PHARMACEUTICALS, INC.

2019 Q1 Form 10-Q Financial Statement

#000156459019015366 Filed on May 02, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q1
Revenue $33.29M $2.900M
YoY Change 1048.07% -84.7%
Cost Of Revenue $3.347M
YoY Change
Gross Profit $29.95M
YoY Change
Gross Profit Margin 89.95%
Selling, General & Admin $89.61M $72.45M
YoY Change 23.69% 88.17%
% of Gross Profit 299.22%
Research & Development $129.1M $96.86M
YoY Change 33.32% 11.35%
% of Gross Profit 431.19%
Depreciation & Amortization $12.20M $3.200M
YoY Change 281.25% 6.67%
% of Gross Profit 40.74%
Operating Expenses $218.7M $169.3M
YoY Change 29.2% 34.93%
Operating Profit -$188.8M -$147.4M
YoY Change 28.07% 38.39%
Interest Expense $7.500M $5.800M
YoY Change 29.31% 176.19%
% of Operating Profit
Other Income/Expense, Net $7.568M $6.129M
YoY Change 23.48% -886.78%
Pretax Income -$181.2M -$141.3M
YoY Change 28.27% 31.68%
Income Tax $695.0K -$62.00K
% Of Pretax Income
Net Earnings -$181.9M -$141.2M
YoY Change 28.82% 31.62%
Net Earnings / Revenue -546.39% -4869.45%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.726M -$1.412M
COMMON SHARES
Basic Shares Outstanding 106.3M 99.87M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.245B $1.568B
YoY Change -20.63% 181.53%
Cash & Equivalents $725.0M $396.1M
Short-Term Investments $519.6M $1.172B
Other Short-Term Assets $81.70M $66.70M
YoY Change 22.49% 268.51%
Inventory $32.00M
Prepaid Expenses
Receivables $33.80M $50.80M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.392B $1.685B
YoY Change -17.4% 182.21%
LONG-TERM ASSETS
Property, Plant & Equipment $568.1M $202.0M
YoY Change 181.24% 55.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $600.0K
YoY Change -99.76%
Other Assets $53.90M $35.20M
YoY Change 53.13% 2292.93%
Total Long-Term Assets $622.0M $237.8M
YoY Change 161.56% -55.69%
TOTAL ASSETS
Total Short-Term Assets $1.392B $1.685B
Total Long-Term Assets $622.0M $237.8M
Total Assets $2.014B $1.923B
YoY Change 4.73% 69.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $22.70M $13.20M
YoY Change 71.97% -47.97%
Accrued Expenses $123.9M $63.80M
YoY Change 94.2% 100.36%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $149.2M $115.4M
YoY Change 29.29% 20.48%
LONG-TERM LIABILITIES
Long-Term Debt $30.00M $30.00M
YoY Change 0.0% -80.0%
Other Long-Term Liabilities $287.9M $23.00M
YoY Change 1151.74% 622.36%
Total Long-Term Liabilities $317.9M $53.00M
YoY Change 499.81% 1564.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $149.2M $115.4M
Total Long-Term Liabilities $317.9M $53.00M
Total Liabilities $467.0M $168.3M
YoY Change 177.48% -44.46%
SHAREHOLDERS EQUITY
Retained Earnings -$2.079B
YoY Change 17.88%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.547B $1.755B
YoY Change
Total Liabilities & Shareholders Equity $2.014B $1.923B
YoY Change 4.73% 69.6%

Cashflow Statement

Concept 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income -$181.9M -$141.2M
YoY Change 28.82% 31.62%
Depreciation, Depletion And Amortization $12.20M $3.200M
YoY Change 281.25% 6.67%
Cash From Operating Activities -$188.5M -$155.7M
YoY Change 21.1% 55.2%
INVESTING ACTIVITIES
Capital Expenditures $44.05M $21.26M
YoY Change 107.22% -41.2%
Acquisitions
YoY Change
Other Investing Activities $146.7M -$113.6M
YoY Change -229.14% -202.16%
Cash From Investing Activities $102.7M -$134.8M
YoY Change -176.14% -279.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $381.9M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $390.9M 41.52M
YoY Change 841.5% 1437.85%
NET CHANGE
Cash From Operating Activities -$188.5M -155.7M
Cash From Investing Activities $102.7M -134.8M
Cash From Financing Activities $390.9M 41.52M
Net Change In Cash $305.1M -249.0M
YoY Change -222.54% 1006.47%
FREE CASH FLOW
Cash From Operating Activities -$188.5M -$155.7M
Capital Expenditures $44.05M $21.26M
Free Cash Flow -$232.6M -$176.9M
YoY Change 31.45% 29.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3496000
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
282300000
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
458000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
226412000
CY2018Q4 us-gaap Inventory Net
InventoryNet
24068000
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
16977000
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33294000
CY2018Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21899000
CY2019Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3347000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
96857000
CY2019Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
89608000
CY2018Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
72447000
CY2019Q1 us-gaap Costs And Expenses
CostsAndExpenses
222082000
CY2018Q1 us-gaap Costs And Expenses
CostsAndExpenses
169304000
CY2019Q1 us-gaap Investment Income Net
InvestmentIncomeNet
7525000
CY2018Q1 us-gaap Investment Income Net
InvestmentIncomeNet
5794000
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
43000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
335000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7568000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6129000
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-181220000
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-141276000
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
695000
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-62000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-181915000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.73
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.41
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
105400000
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
99979000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
360000
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-420000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-181555000
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-141634000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11409000
CY2019Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
784000
CY2019Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
58000
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
381900000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32541000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
360000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
1766431000
CY2018Q1 us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
68210000
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
41890000
CY2018Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
567000
CY2018Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
122000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19463000
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-420000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-181915000
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-141214000
CY2019Q1 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
12210000
CY2018Q1 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
3178000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
32032000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
19584000
CY2019Q1 us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
1089000
CY2018Q1 us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
942000
CY2019Q1 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
21000
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
15041000
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
16766000
CY2019Q1 us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
-12386000
CY2019Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7134000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9418000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
27540000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-17133000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-9042000
CY2019Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-14731000
CY2018Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-11767000
CY2019Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-834000
CY2018Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
26961000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-188510000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-155664000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
44049000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21257000
CY2019Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
256996000
CY2018Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
358433000
CY2019Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
403697000
CY2018Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
244876000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
102652000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-134814000
CY2019Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
9083000
CY2018Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
42094000
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
381900000
CY2019Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
52000
CY2018Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
572000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
390931000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41522000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
305073000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-248956000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
422631000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
646832000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
727704000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
397876000
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
13033000
CY2018Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
10437000
CY2019Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. NATURE OF BUSINESS </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We commenced operations on June 14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on RNA interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, commercial biopharmaceutical company with a sustainable pipeline of RNAi therapeutics to address the needs of patients who have limited or inadequate treatment options. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and early commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. In late 2017, we filed a new drug application and a marketing authorisation application seeking regulatory approval of ONPATTRO<sup style="font-size:85%; vertical-align:top">&#174;</sup> (patisiran), our first product, in the U.S. and Europe, respectively. In August 2018, we received approval for ONPATTRO from the United States Food and Drug Administration and began commercializing and generating product revenues in the U.S. In August 2018, we also received approval of ONPATTRO from the European Commission and in October 2018, began commercializing and generating product revenues outside of the U.S. During 2018, we also submitted regulatory applications for the approval of ONPATTRO in Japan, Canada and Switzerland, and we plan to make regulatory filings in additional markets in Europe and elsewhere throughout 2019.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to risks common to companies in our industry including, but not limited to, uncertainties relating to conducting clinical research and development, the manufacture and supply of products for clinical and commercial use, obtaining and maintaining regulatory approvals and pricing and reimbursement for our products, market acceptance, managing global growth and operating expenses, availability of additional capital, competition, obtaining and enforcing patents, stock price volatility, dependence on collaborative relationships and third-party service providers, dependence on key personnel, potential litigation, product liability claims and government investigations. </p>
CY2018Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
15262000
CY2019Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
135000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
290000000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
230000000
CY2019Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
11723000
CY2018Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
5625000
CY2019Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3026000
CY2018Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3954000
CY2019Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
928000
CY2019Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
9179000
CY2018Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
8709000
CY2019Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
22687000
CY2018Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
97000
CY2019Q1 alny Impairment Of Marketable Debt Securities
ImpairmentOfMarketableDebtSecurities
0
CY2018Q1 alny Impairment Of Marketable Debt Securities
ImpairmentOfMarketableDebtSecurities
0
CY2019Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1049870000
CY2019Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
26000
CY2019Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
87000
CY2019Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1049809000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
884505000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
422000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
884084000
CY2019Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
530231000
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
221281000
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
9290000
CY2019Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1049809000
CY2019Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
1049870000
CY2019Q1 us-gaap Variable Lease Cost
VariableLeaseCost
5047000
CY2019Q1 us-gaap Lease Cost
LeaseCost
14337000
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
7100000
CY2019Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P13Y10M24D
CY2019Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.082
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
11125000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
34530000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
35776000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
35880000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
35575000
CY2019Q1 alny Lessee Operating Lease Liability Payments Due Year Six
LesseeOperatingLeaseLiabilityPaymentsDueYearSix
34674000
CY2019Q1 alny Lessee Operating Lease Liability Payments Due Year Seven And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter
356211000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
543771000
CY2019Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
244494000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
299277000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
32228000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
34826000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
34410000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
34826000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
35270000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
390455000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
562015000
CY2019Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5000000
CY2019Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
77.50
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
381900000
CY2019Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
5600000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32032000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19584000
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14585000
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12672000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
396149000
CY2019Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
439000
CY2019Q1 us-gaap Restricted Cash And Cash Equivalents Current Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList
us-gaap:PrepaidExpenseAndOtherAssetsCurrent
CY2018Q1 us-gaap Restricted Cash And Cash Equivalents Current Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList
us-gaap:PrepaidExpenseAndOtherAssetsCurrent
CY2019Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2306000
CY2018Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1727000
CY2019Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2018Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2018Q2 alny Litigation Settlement Common Stock Issuable From Other Party
LitigationSettlementCommonStockIssuableFromOtherParty
983208

Files In Submission

Name View Source Status
0001564590-19-015366-index-headers.html Edgar Link pending
0001564590-19-015366-index.html Edgar Link pending
0001564590-19-015366.txt Edgar Link pending
0001564590-19-015366-xbrl.zip Edgar Link pending
alny-10q_20190331.htm Edgar Link pending
alny-20190331.xml Edgar Link completed
alny-20190331.xsd Edgar Link pending
alny-20190331_cal.xml Edgar Link unprocessable
alny-20190331_def.xml Edgar Link unprocessable
alny-20190331_lab.xml Edgar Link unprocessable
alny-20190331_pre.xml Edgar Link unprocessable
alny-ex101_348.htm Edgar Link pending
alny-ex311_6.htm Edgar Link pending
alny-ex312_11.htm Edgar Link pending
alny-ex321_8.htm Edgar Link pending
alny-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g40cuqezchcs000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending